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Aims Use of sodium–glucose co-transporter 2 inhibitors (SGLT2i) in real-world heart failure (HF) is poorly characterised.
In contemporary patients with HF and type 2 diabetes mellitus (T2DM) we assessed over time SGLT2i use, clinical
characteristics and outcomes associated with SGLT2i use.
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Methods
and results
Type 2 diabetes patients enrolled in the Swedish HF Registry between 2016–2018 were considered. We performed
multivariable logistic regression models to assess the independent predictors of SGLT2i use and Cox regression
models in a 1:3 propensity score-matched cohort and relevant subgroups to investigate the association between
SGLT2i use and outcomes. Of 6805 eligible HF patients with T2DM, 376 (5.5%) received SGLT2i, whose use
increased over time with 12% of patients on treatment at the end of 2018. Independent predictors of SGLT2i
use were younger age, HF specialty care, ischaemic heart disease, preserved kidney function, and absence of
anaemia. Over a median follow-up of 256 days, SGLT2i use was associated with a 30% lower risk of cardiovascular
(CV) death/first HF hospitalisation (hazard ratio 0.70, 95% confidence interval 0.52–0.95), which was consistent
regardless of ejection fraction, background metformin treatment and kidney function. SGLT2i use was also associated
with a lower risk of all-cause and CV death, HF and CV hospitalisation, and CV death/myocardial infarction/
stroke.
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Conclusion In a contemporary HF cohort with T2DM, SGLT2i use increased over time, was more common with specialist care,
younger age, ischaemic heart disease, and preserved renal function, and was associated with lower mortality and
morbidity.
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Keywords SGLT2 inhibitors • Heart failure • HFmrEF • HFpEF • Outcomes • SwedeHF
*Corresponding author. Department of Medicine, Karolinska Institutet, Heart and Vascular Theme, Karolinska University Hospital, FoU Tema Hjärta Kärl - Norrbacka, S1:02,
17176 Stockholm, Sweden. Tel: +46 7 64165215, Email: gianluigi.savarese@ki.se
†These authors contributed equally.
© 2021 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
This is an open access article under the terms of the Creative Commons Attribution-NonCommercial License, which permits use, distribution and
reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.
2 P.M. Becher et al.
Introduction
Heart failure (HF) is the leading cause of hospitalisation in the
Western world, with the risk of death raising after each HF
hospitalisation.1 Despite advances in treatment, prognosis in HF
with reduced ejection fraction (HFrEF) remains poor, with no
evidence-based treatment available in HF with preserved ejection
fraction (HFpEF) and only limited evidence in HF with mid-range
or mildly reduced ejection fraction (HFmrEF).1
Type 2 diabetes mellitus (T2DM) is an independent risk factor
for the development of HF and both diseases closely influence
each other.2 Prevalence of T2DM is about 25% in patients with
HF,3 which increases to about 40% in hospitalised HF patients.4
T2DM, however, is slightly less common in HFmrEF and HFrEF
compared with HFpEF.5
Over the last 5 years, randomised placebo-controlled trials
have demonstrated sodium–glucose co-transporter 2 inhibitors
(SGLT2i) reducing the risk of hospitalisation for HF by 30–35%
compared with standard of care (SOC) among T2DM patients at
high risk for or with established cardiovascular (CV) disease.6–10
This effect has been shown to be consistent across different levels
of baseline HF risk.11–13 Consequently, several trials have been
initiated to test the hypothesis that SGLT2i may be as effective in
HF regardless of the presence of T2DM. Of these, the DAPA-HF
trial was the first to show a 26% reduction in the risk of CV death
or worsening HF in patients receiving dapagliflozin vs. SOC. More
recently, in the EMPEROR-Reduced trial, empagliflozin was also
observed to reduce the risk of CV death or HF hospitalisation by
25% compared with SOC. Both trials enrolled patients with HFrEF,
and both dapagliflozin and empagliflozin were effective regardless
of the presence of T2DM.9,14,15 Finally, the SOLOIST-WHF trial
recently showed that sotagliflozin reduced the risk of CV death/HF
hospitalisations/visits in T2DM patients who had recently been
hospitalised for HF.16
Sodium–glucose co-transporter 2 inhibitors are a relatively new
treatment, thus limitedly evaluated in real-world settings, partic-
ularly in HF populations.17 Although treatment efficacy can only
be demonstrated by randomised controlled trials, trial populations
may be highly selected, and thus analyses in real-world populations
are helpful to assess generalizability of trial findings and to rule out
any signals of harm.18
Therefore, the aim of the current study was to investigate (i) the
evolving use of SGLT2i; (ii) patient characteristics independently
associated with SGLT2i use; and (iii) the association of SGLT2i use
with outcomes, in an unselected cohort of T2DM patients with HF
across the ejection fraction spectrum (HFpEF, HFmrEF, and HFrEF).
Methods
Study protocol and setting
Data from the Swedish HF registry (SwedeHF) were analysed. The
SwedeHF has been described previously.19 It is a voluntary HF quality
registry founded in 2000. A majority of Swedish hospitals (approx-
imately 60 of 75) enrol patients without financial compensation,
and record approximately 80 variables from adult inpatient wards



















































































.. clinician-judged HF, regardless of ejection fraction, thus including HFrEF,
HFmrEF and HFpEF. Coverage of SwedeHF ranges between 10% for
incident HF (i.e. most patients with new-onset HF are first seen in
outpatient primary care or inpatient emergency departments, which
do not report to SwedeHF) and 54% for prevalent HF.
For the current analysis, patients with HF and T2DM registered
between 1 January 2016 and 31 December 2018 were considered, as
this coincides with the availability of SGLT2i in Sweden. No further
inclusion/exclusion criterion was considered. In SwedeHF, T2DM is
diagnosed according to clinical judgement. Use of SGLT2i and other
glucose-lowering agents was assessed through the Dispensed Drug
Registry, which provides data on medications which are dispensed
(and not only prescribed). A patient was considered as receiving
SGLT2i/other glucose-lowering drugs at baseline if a dispensation was
recorded in the Dispensed Drug Registry in the 5 months prior to or
14 days after the index date, i.e. the date of registration in SwedeHF.
When a patient was registered more than once during the study
period, i.e. 2016–2018, the last registration was selected since more
representative of contemporary care.
Linkage to Statistics Sweden provided socioeconomic data such
as income, level of education, living environment (cohabitating vs.
living alone) and number of children. The National Patient Registry
provided data on additional comorbidities and on the outcomes of
HF hospitalisation, CV hospitalisation, hospitalisation for myocardial
infarction (MI) and stroke. The Cause of Death Registry provided the
outcomes of all-cause and CV death. The linkage of the aforementioned
registries was enabled through a unique personal identification number
that all Swedish residents have regardless of citizenship.
Establishment of the HF registry and this analysis with linking of
the registries was approved by a multisite ethics committee. Individual
patient consent was not required, but patients in Sweden are informed
of entry into national registries and have the option not to participate.
Statistical analysis
Outcomes were a composite of CV death/first HF hospitalisation,
time to all-cause death, CV death, first HF hospitalisation, first CV
hospitalisation, and a composite of CV death/first hospitalisation for
HF/MI/stroke. Data were censored at 31 December 2018 (end of
study), death, or emigration.
In multivariable models, missing data were handled by multiple
imputation using the mice package for 10 datasets and 10 interactions.
Variables included in the models are specified in Table 1. The outcome
of CV death/first HF hospitalisation was included as the Nelson–Aalen
estimator, whereas SGLT2i use was not.
Baseline characteristics were compared in patients receiving vs.
not receiving SGLT2i by Mann–Whitney test (if continuous) and by
chi-squared test (if categorical).
Univariable and multivariable logistic regression models were fitted
in order to investigate patient characteristics (demographics, orga-
nizational factors, clinical characteristics, comorbidities, concomitant
treatments, socioeconomical characteristics) independently associated
with SGLT2i use. Results were reported as odds ratio (OR) with 95%
confidence intervals (CI). Outliers were investigated by Cook’s dis-
tance and multicollinearity by the variance inflation factor. No action
was deemed necessary.
Univariable Cox proportional hazard regression models were fit-
ted to assess crude risk of outcomes in patients receiving vs. those
not receiving SGLT2i. Incidence per 1000 patient-years was calcu-
lated with 95% CI by Poisson regression. Propensity scores (PS) for
© 2021 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
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the use of SGLT2i were calculated using a logistic regression model
including the variables marked with * in Table 1. One-to-three match-
ing with caliper = 0.01/sd(PS) without replacement was thereafter
performed on the average of the PS from the 10 imputed datasets
to match SGLT2i vs. non-SGLT2i-treated patients. The ability of PS
matching to balance the baseline characteristics was assessed by stan-
dardized mean differences, where a value <0.10 was considered not
significant. The independent association between SGLT2i and out-
comes was assessed by Kaplan–Meier curves (with log-rank test) in the
PS-matched cohort. Univariable Cox proportional hazard regression
models in the PS-matched population were used to calculate hazard
ratios (HR) with 95% CI where the matched pairs were modelled using
a frailty term. The proportional hazard assumption was investigated
through the scaled Schoenfeld residuals and found to be fulfilled.
As consistency analysis, in order to take into account potential
cross-over/discontinuation in treatment use that might have impacted
on the results of outcome analyses, we performed additional Cox
regression models in the PS-matched cohort where SGLT2i use was
included as a time-dependent variable. In patients treated with SGLT2i
at baseline, a patient was assumed to be on SGLT2i until the last dispen-
sation recorded +3 months or end of follow-up minus 5 months inde-
pendent of time frame between dispensations. In untreated patients,
crossover was defined as a new SGLT2i dispensation in the Dispensed
Drug Registry and thereafter in the same manner as for patients treated
with SGLT2i at baseline. Patients treated with SGLT2i at baseline were
allowed to crossover no more than once (yes-no) and patients not
receiving SGLT2i at baseline were allowed to crossover no more
than twice (no-yes-no). The analyses were also performed using a
sub-distributional hazard models where death was treated as a com-
peting event.
Subgroup analyses based on ejection fraction strata, background use
of metformin and kidney function [estimated glomerular filtration rate
(eGFR) <60 vs. ≥60 mL/min/1.73 m2] were individually performed in
the PS-matched cohort by including an interaction term between these
variables and SGLT2i in the Cox regression models.
All the analyses were performed on R version 3.6.2. The R code
for all data handling and statistical analyses are found at https://
github.com/KIHeartFailure/sglt2. Variable definitions are available at
https://kiheartfailure.github.io/shfdb3/. A P-value<0.05 was considered
statistically significant.
Results
Between 1 January 2016 and 31 December 2018 there were 6805
patients with HF and T2DM registered in SwedeHF. Median age was
76.0 [interquartile range (IQR) 69.0–82.0] years and 32.1% were
female. In this study, 27.9% had HFpEF, 24.1% HFmrEF and 48.0%
HFrEF.
Time trends in sodium–glucose
co-transporter 2 inhibitor use
At baseline, 376 (5.5%) patients received a SGLT2i, with 16.8% of
them treated with dapagliflozin, 0.5% with canagliflozin and 83.2%
with empagliflozin. As many as 210 (55.9%) were new users of
SGLT2i, i.e. had no dispensation of SGLT2i 5 months prior to the
index date. Figure 1 shows the time trends in SGLT2i use over
time in the study population, with a gradual increase of ∼12% of




















































































Figure 1 Use of sodium–glucose co-transporter 2 inhibitors
over time in the study population.
0.2% on ertugliflozin, 10.2% on dapagliflozin, 0.5% on canagliflozin
and 89.2% on empagliflozin.
Patient characteristics according
to sodium–glucose co-transporter 2
inhibitor use
In the overall population, patients receiving vs. not receiving SGLT2i
were more likely male and younger, had higher income, were more
likely encountered in outpatient care and referred for follow-up to
specialty care and nurse-led HF clinic. They were also more likely
to have HFrEF, shorter duration of HF, lower New York Heart
Association class and N-terminal pro-B-type natriuretic peptide
levels. SGLT2i-treated patients were also more likely to have lower
blood pressure. They were less likely to suffer from anaemia, atrial
fibrillation, kidney disease, chronic obstructive pulmonary disease
and valvular disease, but more likely to have ischaemic heart disease
(IHD) and to be obese. There were no significant differences in use
of HF and other CV treatments across the study groups (Table 1).
In the 1:3 PS-matched cohort of 1444 patients (25% on
SGLT2i), patient characteristics were well matched. As many as
109 (10%) patients who were not receiving SGLT2i at baseline ini-
tiated treatment during follow-up, whereas 39 (11%) patients who
were receiving SGLT2i at baseline discontinued treatment during
follow-up (Table 1).
Independent predictors
of sodium–glucose co-transporter 2
inhibitor use
Of all the variables tested in our multivariable model, independent
predictors were younger age, outpatient setting, referral to
© 2021 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
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Figure 2 Independent predictors of sodium–glucose co-transporter 2 inhibitor (SGLT2i) use. ARNI, angiotensin receptor–neprilysin
inhibitor; COPD, chronic obstructive pulmonary disease; CRT, cardiac resynchronisation therapy; DPP4i, dipeptidyl peptidase 4 inhibitor; EF,
ejection fraction; eGFR, estimated glomerular filtration rate; GLP1-Ra, glucagon-like receptor agonist; HF, heart failure; HFmrEF, heart failure
with mid-range ejection fraction; HFpEF, heart failure with preserved ejection fraction; HFrEF, heart failure with reduced ejection fraction; ICD,
implantable cardioverter-defibrillator; MAP, mean arterial pressure; MRA, mineralocorticoid receptor antagonist; NT-proBNP, N-terminal
pro-B-type natriuretic peptide; NYHA, New York Heart Association; RASi, renin–angiotensin system inhibitor.
nurse-led HF clinic, referral to specialty care, lower blood pres-
sure, use of other glucose-lowering drugs [insulin, metformin,
glucagon-like peptide-1 receptor agonist (GLP1-RA), and dipep-
tidyl peptidase 4 inhibitor], IHD, preserved kidney function, and no
history of anaemia (Figure 2 and online supplementary Table S1).
Outcome analysis
Cardiovascular death or first heart failure hospitalisation
Over a median (IQR) follow-up of 256 (89–524) days, in the overall
cohort event rates for CV death or first HF hospitalisation were

















.. arm, respectively, corresponding to an unadjusted HR of 0.53 (95%
CI 0.40–0.70).
In the PS-matched cohort, event rates were 195 vs. 247 per
1000 patient-years for SGLT2i vs. no-SGLT2i use. Therefore,
SGLT2i was associated with a significant 30% lower risk of CV
death/first HF hospitalisation (HR 0.70, 95% CI 0.52–0.95). The
observed association of SGLT2i use with outcome was statis-
tically significant at 60, 90 days and 1 year but not at 30 days.
Consistency analyses with SGLT2i use as a time-dependent vari-
able and with non-CV death as competing event confirmed
the main analysis results (Figures 3 and 4; online supplementary
Table S2).
© 2021 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
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Figure 3 Kaplan–Meier curves for the risk of cardiovascular
(CV) death or first heart failure (HF) hospitalisation in patients
receiving vs. not receiving sodium–glucose co-transporter 2








































In the overall (i.e. unadjusted analyses) and in the PS-matched
(i.e. adjusted analyses) cohort, SGLT2i use was associated with a
significant lower risk of all-cause death, CV death, first HF hos-
pitalisation, first CV hospitalisation, CV death/first hospitalisation
for HF/MI/stroke, which was confirmed at the consistency analyses
(Figure 4, online supplementary Tables S4–S7).
Subgroup analysis
No significant interaction was observed between HF subtype
(HFpEF vs. HFmrEF vs. HFrEF), concomitant treatment with met-
formin and eGFR <60 vs. ≥60 mL/min/1.73 m2 and the association
of SGLT2i use with risk of CV death/HF hospitalisation (Figure 5;
online supplementary Table S8).
Discussion
In a nationwide, real-world cohort of patients with HF and T2DM,
we found that (i) use of SGLT2i was relatively low but increased
over time; (ii) key patient characteristics independently associated
with SGLT2i use were younger age, HF specialty care, IHD and
preserved kidney function; (iii) use of SGLT2i was associated with
lower mortality (i.e. all-cause and CV death) and lower morbidity
(i.e. CV and HF hospitalisations).
Figure 4 Outcome analysis in the propensity-matched cohort. X-axis is reported in logarithmic scale. CI, confidence interval; CV,
cardiovascular; CVD, cardiovascular death; HF, heart failure; HR, hazard ratio; PS, propensity score; SGLT2i, sodium–glucose co-transporter
2 inhibitor.
© 2021 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
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Figure 5 Subgroup analyses in the propensity-matched cohort. X-axis is reported in a logarithmic scale. CI, confidence interval; eGFR,
estimated glomerular filtration rate; HFmrEF, heart failure with mid-range ejection fraction; HFpEF, heart failure with preserved ejection
fraction; HFrEF, heart failure with reduced ejection fraction; HR, hazard ratio; SGLT2i, sodium–glucose co-transporter 2 inhibitor.
Use of sodium–glucose co-transporter 2
inhibitor in real-world care
Sodium–glucose co-transporter 2 inhibitors are among the most
recent oral anti-hyperglycaemic agents approved for the treat-
ment of T2DM.20 Although SGLT2i were developed for their
glucose-lowering effect, large CV outcome trials showed striking,
early beneficial effects in terms of mortality/HF risk reduction,
which were consistent regardless of the presence and type of
HF.11–13 Based on this evidence, the European Society of Cardiol-
ogy (ESC) guidelines on diabetes recommended the use of SGLT2i
(and/or GLP1-RAs) as first-line therapy for T2DM in patients with
established CV disease, such as those with HF (class IA).21 Con-
sistently, the American Diabetes Association and the European
Association for the Study of Diabetes also recommended SGLT2i
in patients with T2DM and HF.22
Although recommended by international guidelines on diabetes,
SGLT2i are a relatively new treatment and the implementation of
their use in clinical practice might require time. Previous data from
the CHAMP-HF study in the US showed that only 2% of the HF































.. between December 2015 and October 2017.17 Our analysis of
this nationwide Swedish cohort, where the universal health care
system might lead to a more unbiased assessment of treatment
in clinical practice, showed a considerable increase of SGLT2i
use in HF patients since 2016, i.e. the same year EMPA-REG
OUTCOME was published. It might therefore not be surprising
that in our study empagliflozin use was the highest, followed
by dapagliflozin and canagliflozin. Based on these trajectories, a
further increase in SGLT2i use might be expected in the near
future.
In our analysis, key patient characteristics independently asso-
ciated with SGLT2i use were younger age, IHD, preserved kidney
function and better quality of care (i.e. referral to specialty care
or to nurse-led HF clinics). Patients with IHD are considered to
be at very high risk and are usually treated more intensively, which
is consistent with our findings showing higher use of SGLT2i in
patients with IHD. Preserved kidney function was an independent
predictor of SGLT2i use, which is not surprising given that trials
supporting SGLT2i use during our enrolment time excluded
patients with chronic kidney disease, and consequently evidence
for lower eGFR values was limited. However, the CREDENCE
© 2021 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
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and DAPA-CKD trials have recently shown efficacy/safety of
canagliflozin and dapagliflozin, respectively, also in patients with
chronic kidney disease.23,24
Increased use of SGLT2i with younger age and in absence
of anaemia is consistent with the previously observed inverse
relationship between risk and treatment rates, which might be
explained by physicians’ under appreciation of treatment benefits
in older frail patients, with multi-comorbidities and therefore at
higher risk of death.5,25
The strong and independent association between better quality
of care and use of SGLT2i in our analysis is remarkable and
supports the rationale and the need for (i) referring HF patients
to a dedicated follow-up in specialty care or nurse-led HF clinics
where specific HF patient characteristics (e.g. low blood pressure,
impaired kidney function, etc.) might be less seen as an impediment
to implement therapy and up-titrate dosage; (ii) educating primary
care physicians to the use of these relatively new medications; (iii)
bringing trial evidence from the academia and tertiary centres to
less specialised care.
Association of sodium–glucose
co-transporter 2 inhibitor use
with outcomes in real-world heart failure
patients with type 2 diabetes
DAPA-HF and EMPEROR-Reduced have recently demonstrated
that dapagliflozin and empagliflozin improve major CV and renal
outcomes in HFrEF regardless of the presence of T2DM.14,15
Consequently, the US Food and Drug Administration has
approved the use of the SGLT2i dapagliflozin for the treat-
ment of HFrEF in adults with and without T2DM, and a label
for empagliflozin is expected soon. Therefore, dapagliflozin and
presumably empagliflozin are going to become part of the SOC
for HFrEF patients, together with the triple cornerstone therapy
including beta-blockers, mineralocorticoid receptor antagonists
and angiotensin receptor–neprilysin inhibitors/renin–angiotensin
system inhibitors.
Consistently, our analysis shows an association between SGLT2i
use and mortality/morbidity in a real-world HF population where
event rates are higher than in trials due to the more unselected
characteristics of our study cohort. Nevertheless, the HRs for
the association of SGLT2i use with CV death/HF hospitalisation
in our analysis almost exactly replicates the estimates observed
in DAPA-HF and EMPEROR-Reduced (HR 0.74 for HFrEF in our
analysis vs. 0.75 in these trials).14,15 Our analysis included also
patients with HFpEF and HFmrEF, whereas available evidence from
trials is mainly limited to HFrEF. Although the subgroup analy-
sis had as major limitation the small sample size and number of
outcome events, it is encouraging that we did not observe any
interaction between ejection fraction and the association of SGLT2i
with CV death/HF hospitalisation, which might mean similar asso-
ciation of SGLT2i use with outcome across the ejection fraction
spectrum. Notably, the SOLOIST-WHF trial has recently shown
sotagliflozin reducing CV death/HF hospitalisations/visits regard-



















































































.. HF.16 The DELIVER and the EMPEROR-Preserved trials, which are
currently investigating the use of dapagliflozin and empagliflozin,
respectively, will provide evidence on the efficacy of SGLT2i in
patients with HFmrEF and HFpEF (i.e. ejection fraction >40%).26
The EMPERIAL-Preserved trial recently failed to show any effect
of empagliflozin on the primary outcome consisting of 6-min walk
test distance change to week 12.27
Finally, our subgroup analysis suggesting no interaction between
eGFR and the association of SGLT2i with outcomes is also consis-
tent with the findings from the EMPEROR-Reduced and DAPA-HF
trials.14,15 Our data also provide some further background for the
current ESC guidelines on diabetes, recommending SGLT2i regard-
less of background metformin treatment in patients at high/very
high CV risk (including HF).21,28
Limitations
Our study has several limitations that should be acknowledged.
First, although SwedeHF collects many variables that allowed us to
perform extensive adjustments using PS matching, we cannot rule
out the presence of residual confounding or selection bias. Indeed,
observational data allow to investigate the association between
an exposure and outcome, but not to assess causality. The fact
that HRs for mortality in our study were lower than in trials may
indeed suggest that patients had unmeasured characteristics asso-
ciated with lower risk. Second, the limited sample size might impact
the interpretation of subgroup analyses, particularly as regards HF
subtypes. Third, our analysis considered data until 2018, when evi-
dence on SGLT2i in HF was still limited and use of SGLT2i was ori-
ented to the risk reduction of atherosclerotic CV events in patients
with T2DM. Fourth, a majority of patients received empagliflozin.
However, large meta-analyses of randomized controlled trials in
T2DM and HF regardless of T2DM suggest no heterogeneity for
risk reduction of CV death and HF hospitalisation with SGLT2i in
patients with HF.29,30 Finally, SwedeHF coverage is around 54%, and
previous studies show that patients enrolled in this registry are
less sick, more likely male and younger, and better treated than the
overall national HF population.31 Therefore, generalizability of our
results might be interpreted accordingly.
Conclusions
In a real-world population with HF and T2DM, use of SGLT2i is
still low, though increasing over time. One of the key predictors
of SGLT2i use was referral to advanced HF care. Consistently
with evidence from clinical trials, SGLT2i use was associated with
lower mortality and morbidity. These findings highlight the need
for implementing the use of SGLT2i in T2DM patients with HF
regardless of ejection fraction.
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